According to a World Health Organization (WHO) estimation, over 10 million patients suffer from visual impairments and vision loss annually due to corneal diseases or injuries. [6,8] The corneal response to injury involves a highly complicated cascade of events that comprises cell adhesion, migration, differentiation, proliferation, death, and extracellular matrix (ECM) remodeling mediated by immunomodulators and growth factors. [9,10] Conserving the corneal transparency is critical for visual perception. Therefore, any destruction that affects its integrity caused by diseases or trauma like bullous keratopathy, keratoconus, and scarring can lead to blurred eyesight and eventually blindness. [4,11,12] Among all the therapeutic modalities that contributed to corneal irreversible damages including drug and gene therapy and surgical techniques, the keratoplasty with a human donor has offered the best clinical outcome with an 80% rate of success. [2,11,13] However, despite a high success rate, increasing demands for donor tissue and graft rejection due to severe immune response of the hosts are considered as the major reasons for developing an alternative to this procedure. [6,11,13,14] Cell therapies in combination with 3D biocompatible scaffolds have the great potential to replace donor tissue for transplantation or improve wound healing. [15] The potential of cell therapy in corneal wound healing has previously been discussed. [16] 3D scaffolds can mimic the composition and structure of the cornea and